Dr. Anne TsaoFocus: Pleural Mesothelioma
University of Texas
MD Anderson Cancer Center
1515 Holcombe Blvd.
As one of the leading specialists treating mesothelioma in the United States, Dr. Tsao has provided new treatment opportunities for many mesothelioma patients.
About Dr. Tsao
Dr. Tsao is the director of the mesothelioma and thoracic chemo-radiation programs at MD Anderson Cancer Center in Houston, Texas. Dr. Tsao is a specialist in the treatment of thoracic cancers, including pleural mesothelioma. Her work at the MD Anderson Cancer Center has given hope to many patients, families, and the future of mesothelioma treatment.
Medical Degree and Residency
MD University of Chicago Pritzker School of Medicine, 1998. Dr. Tsao completed residency at Indiana University School of Medicine in Internal Medicine (1998-2001) and University of Texas at Houston Medical Oncology (2001-2004).
University of Texas Assistant Professor of Thoracic, Head and Neck Medical Oncology.
Dr. Tsao’s Accomplishments
- Director of mesothelioma treatment at MD Anderson
- Member of the Mesothelioma Applied Research Foundation’s Scientific Advisory Board
- Produces clinical research advancing novel treatments for mesothelioma
- Principal investigator leading several clinical trials currently at MD Anderson
Get Connected To Dr. Anne Tsao
Why Choose Dr. Anne Tsao?
- Leading charge with new novel treatment research
- Director of one of the nation’s top mesothelioma programs
- Member of Meso Foundation Science Advisory Board
Dr. Tsao's Clinical Work
Because mesothelioma is such a rare disease, creating treatment plans specifically catered to the individual with mesothelioma is much harder than with other types of cancer. Dr. Tsao has made advances in her research to make personalized treatment a reality for more patients.
The current problem is that there is a limited amount of treatment options for treating mesothelioma. Dr. Tsao, however, has conducted studies on novel treatment methods as well as personalized care.
Dr. Tsao has also collaborated with mesothelioma specialists across the nation to work towards developing personalized mesothelioma treatment. In the study “Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future,” Dr. Tsao tackled the issue of personalizing care in part because of the expected rise in mesothelioma cases in the next decade. The study analyzed medical procedures with respect to genetic factors that may relate to more individualized care.
Phase I Clinical Trials Combining Chemo and Novel Treatment
Dr. Tsao is currently leading several clinical trials for mesothelioma patients. Her prolific research contributed to 2 studies published in 2013 regarding the combination of systemic chemotherapy (Alimta and cisplatin) and novel drugs that inhibit mesothelioma growth by blocking signaling pathways.
The novel drugs in question were imatinib and cediranib. While the trial involving imatinib didn’t show much of a clinical benefit, cediranib combined with systemic chemotherapy had promising results and is moving forward.
Get connected to clinical trials like these to expand your treatment options today.